Abstract: The present invention relates to methods and kits for treating cardiovascular disease.

Abstract: The disclosure relates to compositions and methods for reducing the risk of developing a lung cancer, colorectal cancer, or metastatic breast cancer in a subject, and methods of treating the same, comprising identifying a subject who has one or more risk factors for lung, colorectal or metastatic breast cancer and carries IL-1 single nucleotide polymorphisms (SNPs) associated with high levels of inflammation.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention relates to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates generally to methods for predicting progression, initiation and susceptibility of osteoarthritis in human subjects using their genotype test results.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention relates generally to methods for predicting progression, initiation and susceptibility of osteoarthritis in human subjects using their genotype test results.

Abstract: The invention provides methods and compositions relating to identification and use of genetic information from the IL-I gene cluster—including the structure and organization of novel IL-I-like genes found within the IL-I locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-I locus—which contains the previously-identified IL-1?, EL-1? and IL-IRN genes, for predicting IL-I associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-I haplotype associated inflammatory phenotypes.

Abstract: The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1?, IL-1? and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of insulin resistance associated pathologies) and for treating IL-1 haplotype associated insulin resistance associated pathologies.

Abstract: The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

Abstract: Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Abstract: The invention provides methods and compositions for the pharmacogenetic analysis of anti-inflammatory compounds, especially for the pharmacogenetic association of responsiveness to rheumatoid arthritis medications that target TNF?.

Abstract: The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1?, EL-1? and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes.

Abstract: A system for providing anonymous access to health information may include an interface, a memory and a web portal. The interface may be operative to receive a test result of a biological sample of an individual and a unique identifier associated with the test result. The individual may not be identifiable by the unique identifier. The memory may be operative to store a record in a database. The record may include the test result and the unique identifier associated with the test result. The web portal may be coupled with the database and may be operative to receive the unique identifier from a user. The web portal may retrieve the record comprising of the unique identifier, and display the test result stored in the record to the user.

Abstract: The methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the specification discloses methods for determining a subject's predisposition to increased risk for myocardial infarction.